Preliminary results show a 94.5% effectiveness rate for Moderna’s coronavirus vaccine in Phase 3 trials. The company expects to request emergency use authorization from the FDA within a few weeks. Dr. Jon LaPook reports. Source
According to copyright-related laws, copy any of our content for publication should indicate the source and link of us, such as:"source: NCOV Live Update", otherwise we have the right to hold accountable.